Stockreport

First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF UCART123 is the First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YORK--(BUSINESS WIRE)-- Regulatory News: Cellectis [Read more]